Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...

Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Novo Nordisk announced it will stop collaborating with Hims & Hers Health regarding the distribution of Wegovy weight loss ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

More than one million people in the UK are already paying for the appetite-suppressing drug, from private clinics which ...

Over the next 12 years through NHS primary care providers, 1.6 million people are expected to receive tirzepatide, a weight ...

Weight loss injections will be available at GP surgeries in England - but only for patients who meet strict eligibility ...